General Press Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
12/22/14Keryx Biopharmaceuticals Announces Commercial Launch of AURYXIA(TM) (ferric citrate) Tablets in the United StatesPrinter Friendly Version
12/08/14Keryx Biopharmaceuticals, Inc. to Present at the Oppenheimer & Co. Inc. 25th Annual Healthcare ConferencePrinter Friendly Version
12/04/14Keryx Biopharmaceuticals Announces Issuance of a New U.S. Patent for Auryxia(TM) (ferric citrate) Covering Orally Administrable FormsPrinter Friendly Version
12/02/14Auryxia(TM) (Ferric Citrate) Phase 2 Data Published in the American Journal of Kidney DiseasePrinter Friendly Version
11/17/14Keryx Biopharmaceuticals Announces Trade Name Auryxia(TM) for Ferric CitratePrinter Friendly Version
11/15/14Keryx Biopharmaceuticals Announces Results From Ferric Citrate Phase 3 Long-Term Safety Extension StudyPrinter Friendly Version
11/14/14Keryx Biopharmaceuticals, Inc. to Present at the Stifel 2014 Healthcare ConferencePrinter Friendly Version
11/06/14Keryx Biopharmaceuticals, Inc. Announces Third Quarter and Nine Month 2014 Financial ResultsPrinter Friendly Version
10/30/14Keryx Biopharmaceuticals, Inc. to Host Conference Call on Third Quarter 2014 Financial ResultsPrinter Friendly Version
10/23/14Keryx Biopharmaceuticals Announces Ferric Citrate Presentations at the Upcoming American Society of Nephrology Kidney Week 2014 Annual MeetingPrinter Friendly Version
10/01/14Keryx Biopharmaceuticals Announces Issuance of a New U.S. Patent for Ferric Citrate Covering Orally Administrable FormsPrinter Friendly Version
09/29/14Keryx Biopharmaceuticals Initiates Pivotal Phase 3 Study of Ferric Citrate for the Treatment of Iron Deficiency Anemia in Patients With Non-Dialysis Dependent Chronic Kidney DiseasePrinter Friendly Version
09/05/14Keryx Biopharmaceuticals, Inc. to Present at the Rodman & Renshaw 16th Annual Global Investment ConferencePrinter Friendly Version
09/05/14Keryx Biopharmaceuticals Receives FDA Approval of Ferric Citrate, a New, Oral Iron-Based Treatment for Dialysis Patients With HyperphosphatemiaPrinter Friendly Version
08/07/14Keryx Biopharmaceuticals, Inc. Announces Second Quarter and Six Month 2014 Financial ResultsPrinter Friendly Version
08/05/14Keryx Biopharmaceuticals, Inc. to Host Conference Call on Second Quarter 2014 Financial ResultsPrinter Friendly Version
07/24/14Zerenex(TM) (Ferric Citrate) Long-Term Phase 3 Study Results Published in the Journal of the American Society of NephrologyPrinter Friendly Version
06/18/14Keryx Biopharmaceuticals Announces Issuance of Two U.S. Patents for Zerenex(TM) Covering Orally Administrable Forms of Ferric CitratePrinter Friendly Version
06/17/14Keryx Biopharmaceuticals, Inc. to Present at the 9th Annual JMP Securities Healthcare ConferencePrinter Friendly Version
06/05/14Keryx Biopharmaceuticals, Inc. to Present at the 35th Annual Goldman Sachs Global Healthcare ConferencePrinter Friendly Version
05/22/14Keryx Receives Notification of PDUFA Date Extension for Zerenex(TM)Printer Friendly Version
05/08/14Keryx Biopharmaceuticals, Inc. Announces First Quarter 2014 Financial ResultsPrinter Friendly Version
05/06/14Keryx Biopharmaceuticals Announces Opening of Boston OfficePrinter Friendly Version
05/05/14Keryx Biopharmaceuticals, Inc. to Host Conference Call on First Quarter 2014 Financial ResultsPrinter Friendly Version
04/15/14Keryx Biopharmaceuticals Strengthens Leadership Team With Key Additions in Sales, Corporate Development and LegalPrinter Friendly Version
04/09/14Keryx Biopharmaceuticals Announces Zerenex(TM) (Ferric Citrate Coordination Complex) Phase 2 Results in Non-Dialysis Dependent Chronic Kidney Disease Selected as a Late Breaking Oral Presentation at the Upcoming National Kidney Foundation 2014 Spring Clinical MeetingPrinter Friendly Version
04/02/14Keryx Biopharmaceuticals Announces EMA Validation of Marketing Authorization Application for Zerenex(TM)Printer Friendly Version
03/17/14Keryx Biopharmaceuticals' Zerenex(TM) Data Selected for Poster Presentation at the AMCP's 26th Annual Meeting and ExpoPrinter Friendly Version
03/12/14Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2013 Financial ResultsPrinter Friendly Version
03/11/14Keryx Biopharmaceuticals, Inc. to Host Conference Call on Fourth Quarter and Year End 2013 Financial ResultsPrinter Friendly Version
03/10/14Keryx Biopharmaceuticals Announces Submission of a Marketing Authorization Application for Zerenex(TM) to the European Medicines AgencyPrinter Friendly Version
02/26/14Keryx Biopharmaceuticals Announces Participation at Upcoming Investor ConferencesPrinter Friendly Version
02/18/14Keryx Biopharmaceuticals Announces the Appointment of Abraham Ceesay as Vice President of MarketingPrinter Friendly Version
02/10/14Keryx Biopharmaceuticals Appoints Greg Madison as Chief Operating OfficerPrinter Friendly Version
02/06/14Keryx Biopharmaceuticals to Present at the 16th Annual BIO CEO & Investor ConferencePrinter Friendly Version
01/22/14Keryx Biopharmaceuticals Announces Pricing of Public Offering of Common StockPrinter Friendly Version
01/21/14Keryx Biopharmaceuticals, Inc. Announces $90 Million Proposed Public Offering of Common StockPrinter Friendly Version
01/21/14Keryx Biopharmaceuticals Announces Appointment of Daniel W. Olmstead as Vice President, Payer AccessPrinter Friendly Version
01/17/14Keryx Biopharmaceuticals Announces Marketing Approval of Ferric Citrate in JapanPrinter Friendly Version
01/07/14Keryx Biopharmaceuticals to Present at the 32nd Annual J.P. Morgan Healthcare ConferencePrinter Friendly Version